A longer patent life for formulated drugs in Australia?

2013 ◽  
Vol 12 (9) ◽  
pp. 656-657
Author(s):  
Charlotte Harrison
Keyword(s):  
Patent Life

scholarly journals Technology of ion implantation of structural materials (patent life-cycle analysis)

2020 ◽  
Vol 709 ◽  
pp. 022073
Author(s):  
V V Ovchinnikov ◽  
I A Kurbatova ◽  
N V Uchevatkina
Keyword(s):  
Life Cycle ◽  
Ion Implantation ◽  
Life Cycle Analysis ◽  
Structural Materials ◽  
Patent Life

Patent life of antiretroviral drugs approved in the US from 1987 to 2007

AIDS Care ◽  
2009 ◽  
Vol 21 (6) ◽  
pp. 760-768 ◽  
Author(s):  
Rosa Rodriguez-Monguio ◽  
Enrique Seoane-Vazquez
Keyword(s):  
Antiretroviral Drugs ◽  
The Us ◽  
Patent Life

Market Structure, Innovation, and Optimal Patent Life

1985 ◽  
Vol 28 (1) ◽  
pp. 223-244 ◽  
Author(s):  
Lawrence M. DeBrock
Keyword(s):  
Market Structure ◽  
Patent Life

Pharmacotherapeuetic Options for the Treatment of Multiple Sclerosis

2012 ◽  
Vol 4 ◽  
pp. CMT.S8661 ◽  
Author(s):  
Alan M. Palmer
Keyword(s):  
Multiple Sclerosis ◽  
Immune Cells ◽  
Cell Adhesion Molecule ◽  
Major Change ◽  
Clinical Development ◽  
Immunomodulatory Drugs ◽  
Amino Acid Peptide ◽  
A Cell ◽  
Patent Life ◽  
Neuro Inflammation

Multiple sclerosis is the most common progressive and disabling neurological condition in young adults. Neuro-inflammation is an early and persistent change and forms the basis of most pharmacotherapy for this disease. Immunomodulatory drugs are mainly biologies (β-interferons, a four amino acid peptide, and a monoclonal antibody to a cell adhesion molecule on the blood-CNS barrier) that either attenuate the inflammatory response or block the movement of immune cells into the CNS. They reduce the rate of relapse, but have little or no effect on the progression of disability. The market landscape for MS drugs is in the midst of major change because the patent life of many of these medicines will soon expire, which will lead to the emergence of biosimilars. In addition, new small molecule immunomodulatory and palliative drugs have entered the market, with more in the pipeline; a number of monoclonal antibodies and other immunomodulatory drugs are also in clinical development.

“NIH-money-for-drug-patent-life” proposal rejected

1997 ◽  
Vol 15 (13) ◽  
pp. 1338-1338
Author(s):  
Jeffrey L Fox
Keyword(s):  
Drug Patent ◽  
Patent Life

Should We Patent Life?

1998 ◽  
Vol 12 (2) ◽  
pp. 15-18 ◽  
Author(s):  
Jeremy Rifkin ◽  
Keyword(s):  
Patent Life

Optimal patent life vs optimal patentability standards

1992 ◽  
Vol 10 (1) ◽  
pp. 81-89 ◽  
Author(s):  
Manfredi M.A. La Manna
Keyword(s):  
Patent Life

THE EFFECTIVE PATENT LIFE OF PHARMACEUTICALS IN NEW ZEALAND — A SIMULATION

Prometheus ◽  
1988 ◽  
Vol 6 (1) ◽  
pp. 120-133
Author(s):  
John Parker
Keyword(s):  
New Zealand ◽  
Patent Life
Sign in / Sign up

Export Citation Format

Share Document